Skip to main content

Table 3 Risk of SPC by lung cancer histology after BC diagnosis (1993–2013)

From: Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea

  Latency (months)
  Total < 12 12–59 60–119 ≥120
  SIR (O/E) 95% CI SIR (O/E) SIR (O/E) SIR (O/E) SIR (O/E)
Lung, bronchus 1.05 (782/748.26) (0.97–1.12) 0.98 (90/91.90) 1.07 (331/309.19) 1.03 (227/220.22) 1.06 (134/126.96)
Squamous cell carcinoma 1.15# (280/243.85) (1.02–1.29) 0.94 (29/30.71) 1.18 (121/102.47) 1.08 (77/71.04) 1.34# (53/39.63)
Adenocarcinoma 1.20# (221/183.65) (1.05–1.37) 1.39 (30/21.61) 1.27# (94/74.26) 1.15 (63/54.55) 1.02 (34/33.23)
Small cell carcinoma 1.06 (99/93.82) (0.86–1.28) 0.69 (8/11.64) 1.10 (43/39.13) 1.13 (31/27.46) 1.09 (17/15.58)
Other and unspecified 0.80# (182/226.95) (0.69–0.93) 0.82 (23/27.95) 0.78# (73/93.32) 0.83 (56/67.16) 0.78 (30/38.51)
  1. SPC: second primary cancer, BC: bladder cancer, SIR: standardized incidence ratio, CI: confidence interval, O/E: Observed/Expected
  2. # significant at alpha = 0.05